Literature DB >> 25001425

Induction of labor in twin pregnancies with oral misoprostol versus vaginal dinoprostone--is it effective and safe?

Georgine Huber1, Heike Schütz, Birgit Seelbach-Göbel.   

Abstract

OBJECTIVE: To compare the effectiveness and safety of oral misoprostol versus vaginal dinoprostone for the induction of labor in twin pregnancies.
METHODS: All twin pregnancies ≥ 34 weeks 0 days that were induced with either misoprostol or dinoprostone in St. Hedwig Hospital between 2002 and 2013 were included in this retrospective study. Length of induction, mode of delivery, maternal and neonatal outcomes were compared between the two groups.
RESULTS: After identifying 186 twin mothers matching the inclusion criteria, 154 women were induced with misoprostol (group A) and 32 with dinoprostone (group B). There were no differences in demographic data between the groups. Rates of successful vaginal delivery (53.9% versus 56.3%) and length of induction to delivery (30.2 h versus 26.9 h) were also similar. There were slightly higher rates of postpartum hemorrhage in group B (16.6% versus 10.8%), but without reaching statistical significance. Neonatal outcomes regarding umbilical artery pH <7.20 and one minute Apgar also were without significant differences.
CONCLUSIONS: Study data indicate that oral misoprostol and vaginal dinoprostone are similarly effective and safe for the induction of labor in twin gestations. Further trials with larger series are needed to confirm these results.

Entities:  

Keywords:  Dinoprostone; labor induction; misoprostol; time of delivery; twin gestation

Mesh:

Substances:

Year:  2014        PMID: 25001425     DOI: 10.3109/14767058.2014.942629

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  The effect of induction method in twin pregnancies: a secondary analysis for the twin birth study.

Authors:  Elad Mei-Dan; Elizabeth V Asztalos; Andrew R Willan; Jon F R Barrett
Journal:  BMC Pregnancy Childbirth       Date:  2017-01-06       Impact factor: 3.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.